Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2b randomized, double-blind, placebo-controlled study of Nitric-oxide in Pulmonary-hypertension patients associated with Chronic Obstructive Pulmonary Disease

Next Previous
Search
Trial Profile

Phase 2b randomized, double-blind, placebo-controlled study of Nitric-oxide in Pulmonary-hypertension patients associated with Chronic Obstructive Pulmonary Disease

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 19 Nov 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nitric oxide (Primary)
  • Indications Pulmonary hypertension
  • Focus Therapeutic Use

    • Most Recent Events

    • 07 Nov 2018 According to the Bellerophon Therapeutics media release, the company expects to initiate this trial in 2019.
    • 17 May 2018 According to the Bellerophon Therapeutics media release, company in conjunction with its steering committee finalized the design of this trial and agreement with the FDA has been reached on the design of this trial.
    • 17 May 2018 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top